期刊文献+

PPARs激动剂延缓动脉粥样硬化的研究进展 被引量:7

Peroxisome proliferators-activated receptor agonists delays the formation of arteriosclerosis
原文传递
导出
摘要 过氧化物酶体增殖物激活受体(PPARs),是配体激活的转录因子,属于核受体超家族成员。PPARs广泛参与机体的脂质代谢、糖代谢、能量代谢、细胞生长分化及生殖过程,并与动脉粥样硬化密切相关,PPARs激动剂参与延缓动脉粥样硬化进程。 Peroxisome proliferators-activated receptors (PPARs) are ligand activated transcriptional factors and belonging to the nuclear receptor superfamily. PPARs play important roles in the regulation of lipid and glucose metabolism, energy homeostasis, cell proliferation, differentiation and reproduction. Furthermore, PPARs agonists were closely correlated to atherosclerosis and involved in delaying the formation of atherosclerosis.
出处 《中国实用内科杂志》 CAS CSCD 北大核心 2010年第7期648-649,共2页 Chinese Journal of Practical Internal Medicine
关键词 过氧化物酶体增殖激活受体 激动剂 动脉粥样硬化 peroxisome proliferators-activated receptor agonists atherosclerosis
  • 相关文献

参考文献5

  • 1Hamza MS, Pott S, Vega VB. De-novo identification of PPARgamma/RXR binding sites and direct targets during adipogenesis[ J]. PLOS ONE,2009,4 (3) : e4907.
  • 2Meredith D, Panchatcharam M. Dominant-negative loss of PPAR- gamma function enhances smooth muscle cell proliferation, migration, and vascular remodeling[ J]. Arterioscler Thromb Vasc Biol, 2009,29(4) :465 -471.
  • 3Lim HJ, Lee S. PPAR delta agonist L-165041 inhibits rat vascular smooth muscle cell proliferation and migration via inhibition of cell cycle [ J ]. Atherosclerosis ,2009,202 (2) :446 - 454.
  • 4Mannucci E, Monami M, Di Bari M. Cardiac safety profile of rosiglitazone A comprehensive meta-analysis of randomized clinical trials [ J]. Int J Cardial,2009,131 : [ Epub ahead of print].
  • 5骆雷鸣,朱启伟,朱兵,李妍涵,顾洁,李溪远,马琴,曾强,杨雪,吴红梅,毛利,叶平.国产苯扎贝特对高三酰甘油血症脂代谢及糖代谢影响的研究[J].中国实用内科杂志,2009,29(4):350-353. 被引量:12

二级参考文献10

  • 1Inaba T,Yagyu H, Itabashi N, et al. Cholesterol reduction and ather- osclerosis inhibition by bezafibrate in low-density lipoprotein receptor knockout mice[ J]. Hypertens Res,2008,31 (5) :999 - 1005.
  • 2Tenenbaum A, Motro M, Fisman EZ, et al. Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease [ J ]. Circulation ,2004,109:2197 - 2202.
  • 3Arcavi L, Behar S, Caspi A, et al. High fasting glucose levels as a predictor of worse clinical outcome in patients with coronary artery disease: results from the Bezafibrate Infarction Prevention (BIP) study[ J]. Am Heart J ,2004,147 ( 2 ) :239 - 245.
  • 4Hrebicek J. PPARs:the role in glucose and lipid homeostasis,insulin resistance and atherosclerosis[ J]. Cesk Fysiol,2004,53 ( 1 ) : 4-16.
  • 5Tenenbaum A, Motro M, Fisman EZ. Dual and pan-peroxisome proliferator-activated receptors ( PPAR ) co-agonism : the bezafibrate lessons [ J ]. C ardiovasc Diabetol, 2005,16 ( 4 ) : 14.
  • 6Nagasawa T, Inada Y, Nakano S, et al. Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARδ agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet European[ J]. J Pharmacology,2006,536( 1 -2) :182 - 191.
  • 7Nakano S, Inada Y, Masuzaki H, et al. Bezafibrate regulates the expression and enzyme activity of 11 β-hydroxysteroid dehydrogenase type 1 in murine adipose tissue and 333-L1 adipocytes [ J]. Am J Physiol Endocrinol Metab,2007,292(4) :E1213 -E1222.
  • 8Stimson RH, Walker BR. Glucocorticoids and 11β-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome[ J]. Minerva Endocrinol,2007,32 ( 3 ) : 141 - 159.
  • 9Mori Y, Tokutate Y, Oana F, et al. Bezafibrate-induced changes over time in the expression of uncoupling protein(UCP) mRNA in the tissues-a study in spontaneously type 2 diabetic rats with visceral obesity [ J ]. J Atheroscler Thromb,2004,11 (4) :224 - 231.
  • 10Hiuge A, Tenenbaum A, Maeda N, et al. Effects of peroxisome proliferator-activated receptor ligands, bezafibrate and fenofi-brate, on adiponectin level [ J ]. Arterioscler Thromb Vasc Biol, 2007,27:635 - 641.

共引文献11

同被引文献72

引证文献7

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部